Currently, CKD4/6 inhibitors, mTOR (mammalian target of rapamycin) inhibitors and PI3K (phosphatidylinositol-3 kinase) inhibitors are investigated in order to overcome tumor resistance occurred through genetic and molecular changes (25). Here, MTOR is linked to neoplasm.